Nortriptyline influences protein pathways involved in carbohydrate metabolism and actin-related processes in a rat gene-environment model of depression

European Neuropsychopharmacology

Volumn 21, Issue 7, 2011, Pages 545-562

  Piubelli, Chiara ^a   Gruber, Susanne ^b   El Khoury, Aram ^b   Mathé, Aleksander A ^b   Domenici, Enrico ^a   Carboni, Lucia ^a  

^a GSK   (Italy)

^b KAROLINSKA INSTITUTE   (Sweden)

Author keywords

2 D electrophoresis; Hippocampus; Maternal separation; Nortriptyline; Pre frontal cortex; Proteomics

Indexed keywords

ACTIN; CARBOHYDRATE; CYTOSKELETON PROTEIN; NORTRIPTYLINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARBOHYDRATE METABOLISM; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; FORCED SWIMMING TEST; FRONTAL CORTEX; GENOTYPE ENVIRONMENT INTERACTION; HIPPOCAMPUS; IMMOBILIZATION; INTRACELLULAR TRANSPORT; MORPHOGENESIS; NEURITE; NONHUMAN; NUCLEOTIDE METABOLISM; PREFRONTAL CORTEX; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN POLYMERIZATION; PROTEOMICS; RAT; SYNAPTIC TRANSMISSION;

ACTINS; ANIMALS; ANTIDEPRESSIVE AGENTS; BRAIN; CARBOHYDRATE METABOLISM; CYTOSKELETAL PROTEINS; DEPRESSION; DEPRESSIVE DISORDER; DISEASE MODELS, ANIMAL; ENVIRONMENT; MALE; MATERNAL DEPRIVATION; NORTRIPTYLINE; PROTEOME; RATS; SWIMMING; SYNAPTIC TRANSMISSION;

EID: 79957471348     PISSN: 0924977X     EISSN: 0924977X     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2010.11.003     Document Type: Article

References (76)

1. aan het Rot M., Mathew S.J., Charney D.S. Neurobiological mechanisms in major depressive disorder. CMAJ 2009, 180:305-313.
2. Allen P.J., D'Anci K.E., Kanarek R.B., Renshaw P.F. Chronic creatine supplementation alters depression-like behavior in rodents in a sex-dependent manner. Neuropsychopharmacology 2010, 35:534-546.
3. Amital D., Vishne T., Roitman S., Kotler M., Levine J. Open study of creatine monohydrate in treatment-resistant posttraumatic stress disorder. J. Clin. Psychiatry 2006, 67:836-837.
4. Bartolomucci A., Leopardi R. Stress and depression: preclinical research and clinical implications. PLoS ONE 2009, 4:e4265.
5. Beasley C.L., Pennington K., Behan A., Wait R., Dunn M.J., Cotter D. Proteomic analysis of the anterior cingulate cortex in the major psychiatric disorders: evidence for disease-associated changes. Proteomics 2006, 6:3414-3425.
6. Berton O., Nestler E.J. New approaches to antidepressant drug discovery: beyond monoamines. Nat. Rev. Neurosci. 2006, 7:137-151.
7. Bianchi M., Hagan J.J., Heidbreder C.A. Neuronal plasticity, stress and depression: involvement of the cytoskeletal microtubular system?. Curr. Drug Targets CNS Neurol. Disord. 2005, 4:597-611.
8. Bianchi M., Fone K.C., Shah A.J., Atkins A.R., Dawson L.A., Heidbreder C.A., Hagan J.J., Marsden C.A. Chronic fluoxetine differentially modulates the hippocampal microtubular and serotonergic system in grouped and isolation reared rats. Eur. Neuropsychopharmacol. 2009, 19:778-790.
9. Bianchi M., Shah A.J., Fone K.C., Atkins A.R., Dawson L.A., Heidbreder C.A., Hows M.E., Hagan J.J., Marsden C.A. Fluoxetine administration modulates the cytoskeletal microtubular system in the rat hippocampus. Synapse 2009, 63:359-364.
10. Carboni L., Piubelli C., Pozzato C., Astner H., Arban R., Righetti P.G., Hamdan M., Domenici E. Proteomic analysis of rat hippocampus after repeated psychosocial stress. Neuroscience 2006, 137:1237-1246.
11. Carboni L., Vighini M., Piubelli C., Castelletti L., Milli A., Domenici E. Proteomic analysis of rat hippocampus and frontal cortex after chronic treatment with fluoxetine or putative novel antidepressants: CRF1 and NK1 receptor antagonists. Eur. Neuropsychopharmacol. 2006, 16:521-537.
12. Castren E. Neurotrophic effects of antidepressant drugs. Curr. Opin. Pharmacol. 2004, 4:58-64.
13. Conti B., Maier R., Barr A.M., Morale M.C., Lu X., Sanna P.P., Bilbe G., Hoyer D., Bartfai T. Region-specific transcriptional changes following the three antidepressant treatments electro convulsive therapy, sleep deprivation and fluoxetine. Mol. Psychiatry 2007, 12:167-189.
14. Cryan J.F., Slattery D.A. Animal models of mood disorders: recent developments. Curr. Opin. Psychiatry 2007, 20:1-7.
15. Dennis G., Sherman B.T., Hosack D.A., Yang J., Gao W., Lane H.C., Lempicki R.A. DAVID: Database for Annotation, Visualization, and Integrated Discovery. Genome Biol. 2003, 4:3.
16. Donati R.J., Rasenick M.M. G protein signaling and the molecular basis of antidepressant action. Life Sci. 2003, 73:1-17.
17. Dranovsky A., Hen R. Hippocampal neurogenesis: regulation by stress and antidepressants. Biol. Psychiatry 2006, 59:1136-1143.
18. Drevets W.C., Bogers W., Raichle M.E. Functional anatomical correlates of antidepressant drug treatment assessed using PET measures of regional glucose metabolism. Eur. Neuropsychopharmacol. 2002, 12:527-544.
19. Duman C.H., Schlesinger L., Terwilliger R., Russell D.S., Newton S.S., Duman R.S. Peripheral insulin-like growth factor-I produces antidepressant-like behavior and contributes to the effect of exercise. Behav. Brain Res. 2009, 198:366-371.
20. Dunbar J.A., Reddy P., vis-Lameloise N., Philpot B., Laatikainen T., Kilkkinen A., Bunker S.J., Best J.D., Vartiainen E., Kai L.S., Janus E.D. Depression: an important comorbidity with metabolic syndrome in a general population. Diab. Care 2008, 31:2368-2373.
21. Eissa Ahmed A.A., Al-Rasheed N.M., Al-Rasheed N.M. Antidepressant-like effects of rosiglitazone, a PPARgamma agonist, in the rat forced swim and mouse tail suspension tests. Behav. Pharmacol. 2009, 20:635-642.
22. El Khoury A., Gruber S.H., Mork A., Mathe A.A. Adult life behavioral consequences of early maternal separation are alleviated by escitalopram treatment in a rat model of depression. Prog. Neuropsychopharmacol. Biol. Psychiatry 2006, 30:535-540.
23. Gillman P.K. Tricyclic antidepressant pharmacology and therapeutic drug interactions updated. Br. J. Pharmacol. 2007, 151:737-748.
24. Grunbaum-Novak N., Taler M., Gil-Ad I., Weizman A., Cohen H., Weizman R. Relationship between antidepressants and IGF-1 system in the brain: possible role in cognition. Eur. Neuropsychopharmacol. 2008, 18:431-438.
25. Hammen C. Stress and depression. Annu. Rev. Clin. Psychol. 2005, 1:293-319.
26. Herbert B., Galvani M., Hamdan M., Olivieri E., MacCarthy J., Pedersen S., Righetti P.G. Reduction and alkylation of proteins in preparation of two-dimensional map analysis: why, when, and how?. Electrophoresis 2001, 22:2046-2057.
27. Holmes P.V. Rodent models of depression: reexamining validity without anthropomorphic inference. Crit. Rev. Neurobiol. 2003, 15:143-174.
28. Horesh N., Klomek A.B., Apter A. Stressful life events and major depressive disorders. Psychiatry Res. 2008, 160:192-199.
29. Hoshaw B.A., Malberg J.E., Lucki I. Central administration of IGF-I and BDNF leads to long-lasting antidepressant-like effects. Brain Res. 2005, 1037:204-208.
30. Jeannotte A.M., McCarthy J.G., Redei E.E., Sidhu A. Desipramine modulation of alpha-, gamma-synuclein, and the norepinephrine transporter in an animal model of depression. Neuropsychopharmacology 2009, 34:987-998.
31. Kanemaru K., Diksic M. The Flinders Sensitive Line of rats, a rat model of depression, has elevated brain glucose utilization when compared to normal rats and the Flinders Resistant Line of rats. Neurochem. Int. 2009, 55:655-661.
32. Katayama T., Hattori T., Yamada K., Matsuzaki S., Tohyama M. Role of the PACAP-PAC1-DISC1 and PACAP-PAC1-stathmin1 systems in schizophrenia and bipolar disorder: novel treatment mechanisms?. Pharmacogenomics 2009, 10:1967-1978.
33. Katon W.J. The comorbidity of diabetes mellitus and depression. Am. J. Med. 2008, 121:S8-S15.
34. Kennedy S.H., Konarski J.Z., Segal Z.V., Lau M.A., Bieling P.J., McIntyre R.S., Mayberg H.S. Differences in brain glucose metabolism between responders to CBT and venlafaxine in a 16-week randomized controlled trial. Am. J. Psychiatry 2007, 164:778-788.
35. Khawaja X., Xu J., Liang J.J., Barrett J.E. Proteomic analysis of protein changes developing in rat hippocampus after chronic antidepressant treatment: implications for depressive disorders and future therapies. J. Neurosci. Res. 2004, 75:451-460.
36. Landgrebe J., Welzl G., Metz T., van Gaalen M.M., Ropers H., Wurst W., Holsboer F. Molecular characterisation of antidepressant effects in the mouse brain using gene expression profiling. J. Psychiatr. Res. 2002, 36:119-129.
37. Malberg J.E., Blendy J.A. Antidepressant action: to the nucleus and beyond. Trends Pharmacol. Sci. 2005, 26:631-638.
38. Malberg J.E., Platt B., Rizzo S.J., Ring R.H., Lucki I., Schechter L.E., Rosenzweig-Lipson S. Increasing the levels of insulin-like growth factor-I by an IGF binding protein inhibitor produces anxiolytic and antidepressant-like effects. Neuropsychopharmacology 2007, 32:2360-2368.
39. Mayberg H.S., Brannan S.K., Tekell J.L., Silva J.A., Mahurin R.K., McGinnis S., Jerabek P.A. Regional metabolic effects of fluoxetine in major depression: serial changes and relationship to clinical response. Biol. Psychiatry 2000, 48:830-843.
40. McBean D.E., Ritchie I.M., Olverman H.J., Kelly P.A. Effects of the specific serotonin reuptake inhibitor, citalopram, upon local cerebral blood flow and glucose utilisation in the rat. Brain Res. 1999, 847:80-84.
41. McHugh P.C., Rogers G.R., Loudon B., Glubb D.M., Joyce P.R., Kennedy M.A. Proteomic analysis of embryonic stem cell-derived neural cells exposed to the antidepressant paroxetine. J. Neurosci. Res. 2008, 86:306-316.
42. McIntyre R.S., Soczynska J.K., Konarski J.Z., Woldeyohannes H.O., Law C.W., Miranda A., Fulgosi D., Kennedy S.H. Should depressive syndromes be reclassified as "Metabolic Syndrome Type II"?. Ann. Clin. Psychiatry 2007, 19:257-264.
43. McIntyre R.S., Rasgon N.L., Kemp D.E., Nguyen H.T., Law C.W., Taylor V.H., Woldeyohannes H.O., Alsuwaidan M.T., Soczynska J.K., Kim B., Lourenco M.T., Kahn L.S., Goldstein B.I. Metabolic syndrome and major depressive disorder: co-occurrence and pathophysiologic overlap. Curr. Diab. Rep. 2009, 9:51-59.
44. Moretti A., Gorini A., Villa R.F. Affective disorders, antidepressant drugs and brain metabolism. Mol. Psychiatry 2003, 8:773-785.
45. Nakatani N., Ohnishi T., Iwamoto K., Watanabe A., Iwayama Y., Yamashita S., Ishitsuka Y., Moriyama K., Nakajima M., Tatebayashi Y., Akiyama H., Higuchi T., Kato T., Yoshikawa T. Expression analysis of actin-related genes as an underlying mechanism for mood disorders. Biochem. Biophys. Res. Commun. 2007, 352:780-786.
46. Nonogaki K., Iguchi A. Role of central neural mechanisms in the regulation of hepatic glucose metabolism. Life Sci. 1997, 60:797-807.
47. O'Brien S.M., Scott L.V., Dinan T.G. Cytokines: abnormalities in major depression and implications for pharmacological treatment. Hum. Psychopharmacol. 2004, 19:397-403.
48. Overstreet D.H., Friedman E., Mathe A.A., Yadid G. The Flinders Sensitive Line rat: a selectively bred putative animal model of depression. Neurosci. Biobehav. Rev. 2005, 29:739-759.
49. Parker K.C., Walsh R.J., Salajegheh M., Amato A.A., Krastins B., Sarracino D.A., Greenberg S.A. Characterization of human skeletal muscle biopsy samples using shotgun proteomics. J. Proteome Res. 2009, 8:3265-3277.
50. Perkins D.N., Pappin D.J., Creasy D.M., Cottrell J.S. Probability-based protein identification by searching sequence databases using mass spectrometry data. Electrophoresis 1999, 20:3551-3567.
51. Petersen A., Wortwein G., Gruber S.H., El-Khoury A., Mathe A.A. Nortriptyline mediates behavioral effects without affecting hippocampal cytogenesis in a genetic rat depression model. Neurosci. Lett. 2009, 451:148-151.
52. Pittenger C., Duman R.S. Stress, depression, and neuroplasticity: a convergence of mechanisms. Neuropsychopharmacology 2008, 33:88-109.
53. Piubelli, C., Vighini, M., Mathé, A.A., Domenici E., Carboni, L., 2010-a. Escitalopram modulates neuron-remodelling proteins in a rat gene-environment interaction model of depression as revealed by proteomics. Part I: genetic background. Int. J. Neuropsychopharmacol. 8, 1-38.
54. Piubelli, C., Vighini, M., Mathé, A.A., Domenici E., Carboni, L., 2010-b. Escitalopram affects cytoskeleton and synaptic plasticity pathways in a rat gene-environment interaction model of depression as revealed by proteomics. Part II: environmental challenge. Int. J. Neuropsychopharmacol. 8, 1-22.
55. Porsolt R.D., Le Pichon M., Jalfre M. Depression: a new animal model sensitive to antidepressant treatments. Nature 1977, 266:730-732.
56. Rasgon N.L., Kenna H.A., Williams K.E., Powers B., Wroolie T., Schatzberg A.F. Rosiglitazone add-on in treatment of depressed patients with insulin resistance: a pilot study. Sci. World J. 2010, 10:321-328.
57. Reichenstein M., Rehavi M., Pinhasov A. Involvement of pituitary adenylate cyclase activating polypeptide (PACAP) and its receptors in the mechanism of antidepressant action. J. Mol. Neurosci. 2008, 36:330-338.
58. Roitman S., Green T., Osher Y., Karni N., Levine J. Creatine monohydrate in resistant depression: a preliminary study. Bipolar Disord. 2007, 9:754-758.
59. Rosa A.O., Kaster M.P., Binfare R.W., Morales S., Martin-Aparicio E., Navarro-Rico M.L., Martinez A., Medina M., Garcia A.G., Lopez M.G., Rodrigues A.L. Antidepressant-like effect of the novel thiadiazolidinone NP031115 in mice. Prog. Neuropsychopharmacol. Biol. Psychiatry 2008, 32:1549-1556.
60. Santos P.M., Scaini G., Rezin G.T., Benedet J., Rochi N., Jeremias G.C., Carvalho-Silva M., Quevedo J., Streck E.L. Brain creatine kinase activity is increased by chronic administration of paroxetine. Brain Res. Bull. 2009, 80:327-330.
61. Schloss P., Henn F.A. New insights into the mechanisms of antidepressant therapy. Pharmacol. Ther. 2004, 102:47-60.
62. Schubert V., Dotti C.G. Transmitting on actin: synaptic control of dendritic architecture. J. Cell Sci. 2007, 120:205-212.
63. Shao L., Martin M.V., Watson S.J., Schatzberg A., Akil H., Myers R.M., Jones E.G., Bunney W.E., Vawter M.P. Mitochondrial involvement in psychiatric disorders. Ann. Med. 2008, 40:281-295.
64. Sillaber I., Panhuysen M., Henniger M.S., Ohl F., Kuhne C., Putz B., Pohl T., Deussing J.M., Paez-Pereda M., Holsboer F. Profiling of behavioral changes and hippocampal gene expression in mice chronically treated with the SSRI paroxetine. Psychopharmacology (Berl) 2008, 200:557-572.
65. Smith G.S., Ma Y., Dhawan V., Gunduz H., Carbon M., Kirshner M., Larson J., Chaly T., Belakhleff A., Kramer E., Greenwald B., Kane J.M., Laghrissi-Thode F., Pollock B.G., Eidelber D. Serotonin modulation of cerebral glucose metabolism measured with positron emission tomography (PET) in human subjects. Synapse 2002, 45:105-112.
66. Tanis K.Q., Duman R.S. Intracellular signaling pathways pave roads to recovery for mood disorders. Ann. Med. 2007, 39:531-544.
67. Tashiro A., Hongo M., Ota R., Utsumi A., Imai T. Hyper-insulin response in a patient with depression. Changes in insulin resistance during recovery from depression. Diab. Care 1997, 20:1924-1925.
68. Uher R. The implications of gene-environment interactions in depression: will cause inform cure?. Mol. Psychiatry 2008, 13:1070-1078.
69. Uher R., Perroud N., Ng M., Hauser J., Henigsberg N., Maier W., Mors O., Placentino A., Rietschel M., Souery D., Zagar T., Czerski P., Jerman B., Larsen E., Schulze T., Zobel A., Cohen-Wooods S., Pirlo K., Butler A., Muglia P., Barnes M., Lathrop M., Farmer A., Breen B., Aitchison K., Craig I., Lewis C., McGuffin P. Genome-wide pharmacogenetics of antidepressant response in the GENDEP project. Am. J. Psychiatry 2010, 167:555-564.
70. Umhau J.C., Petrulis S.G., Diaz R., Rawlings R., George D.T. Blood glucose is correlated with cerebrospinal fluid neurotransmitter metabolites. Neuroendocrinology 2003, 78:339-343.
71. Vaudry D., Falluel-Morel A., Bourgault S., Basille M., Burel D., Wurtz O., Fournier A., Chow B.K., Hashimoto H., Galas L., Vaudry H. Pituitary adenylate cyclase-activating polypeptide and its receptors: 20years after the discovery. Pharmacol. Rev. 2009, 61:283-357.
72. Weber-Hamann B., Blum W.F., Kratzsch J., Gilles M., Heuser I., Deuschle M. Insulin-like growth factor-I (IGF-I) serum concentrations in depressed patients: relationship to saliva cortisol and changes during antidepressant treatment. Pharmacopsychiatry 2009, 42:23-28.
73. Winokur A., Maislin G., Phillips J.L., Amsterdam J.D. Insulin resistance after oral glucose tolerance testing in patients with major depression. Am. J. Psychiatry 1988, 145:325-330.
74. Yadid G., Nakash R., Deri I., Tamar G., Kinor N., Gispan I., Zangen A. Elucidation of the neurobiology of depression: insights from a novel genetic animal model. Prog. Neurobiol. 2000, 62:353-378.
75. Yang H.J., Li Y.F., Zhang H.T., Zhang F.Q., Zhao N., Gong Z.H., Luo Z.P. Up-regulation of microtubule-associated protein 4 and drebrin A mRNA expression by antidepressants in rat hippocampus following chronic stress. Neurosci. Lett. 2003, 351:206-208.
76. Yang C., Wang G., Wang H., Liu Z., Wang X. Cytoskeletal alterations in rat hippocampus following chronic unpredictable mild stress and re-exposure to acute and chronic unpredictable mild stress. Behav. Brain Res. 2009, 205:518-524.